Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the naturally occurring pineal gland peptide epithalamin. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epitalon is the most studied bioregulator peptide for longevity applications. Its primary mechanism of interest is the activation of telomerase — the enzyme responsible for maintaining telomere length, a key biomarker of cellular aging.

This protocol outlines the practical framework for using Epitalon in a longevity-focused regimen, covering dose selection, cycle design, combination strategies, and the monitoring approach necessary to assess whether the intervention is producing measurable effects.

Mechanism overview

Epitalon's longevity relevance centers on three interconnected pathways.

Telomerase activation: Epitalon has been shown to activate telomerase in human somatic cells in vitro, enabling the addition of telomeric repeat sequences (TTAGGG) to chromosome ends. Telomere shortening is a hallmark of cellular aging — when telomeres reach a critical length, cells enter replicative senescence or apoptosis. By reactivating telomerase in differentiated cells (where it is normally silenced), Epitalon may slow or partially reverse this component of the aging process. This has been demonstrated in cell culture studies and in animal models, though controlled human clinical trials remain limited.

Pineal gland support and melatonin regulation: Epitalon stimulates melatonin production from the pineal gland. Age-related pineal calcification leads to declining melatonin output, which affects sleep architecture, circadian rhythm stability, and antioxidant defense. By supporting pineal function, Epitalon may help restore youthful melatonin secretion patterns. Russian clinical studies in elderly patients reported improved evening melatonin peaks following Epithalamin (the natural extract predecessor) administration.

Neuroendocrine normalization: Beyond melatonin, Epitalon appears to influence the broader neuroendocrine axis, including cortisol rhythmicity and gonadotropin signaling. The practical significance of these effects for a longevity protocol is secondary to the telomerase and melatonin pathways but may contribute to the overall anti-aging profile.

Dose selection

Standard dose: 5 mg per day, administered as a single daily injection

Higher dose: 10 mg per day, either as a single injection or split into two 5 mg doses (morning and evening)

The 5 mg dose is derived from the most commonly referenced clinical and practitioner protocols. The 10 mg dose is used by some practitioners seeking a more intensive effect during the short treatment window, though direct dose-response comparisons in humans have not been published.

Starting recommendation: Begin at 5 mg daily for the first cycle. If well-tolerated and telomere or melatonin markers do not show meaningful change after two complete cycles, consider increasing to 10 mg daily for subsequent cycles.

Body weight adjustment is not standard practice for Epitalon dosing. The peptide acts as a bioregulator — a signaling molecule that triggers endogenous processes — rather than as a pharmacological agent requiring weight-based titration.

Route and administration

Route: Subcutaneous injection

Preferred sites: Abdominal subcutaneous tissue (lower abdomen, rotating left and right of the navel) or upper outer arm

Needle gauge: 29-31 gauge, 0.5-inch insulin syringe

Volume: Depends on reconstitution concentration. A common reconstitution is 2 mL bacteriostatic water per 10 mg vial, yielding 5 mg per mL (0.5 mL for a 2.5 mg dose, 1 mL for a 5 mg dose).

Administration timing: Evening administration (1-2 hours before bed) is preferred when optimizing for melatonin support, as the peptide's pineal-stimulating effects align with the natural evening melatonin rise. Morning administration is acceptable if evening timing is impractical.

Some practitioners and compounding sources reference intramuscular or intravenous routes. Subcutaneous is sufficient for bioregulator peptides and is the most practical for self-administration. There is no published evidence that IM or IV routes provide superior outcomes for Epitalon.

Cycle structure

Epitalon follows a distinctive cycling pattern that differs markedly from most peptide protocols. Rather than continuous daily use over weeks, Epitalon is administered in short, intensive bursts followed by extended rest periods.

Standard cycle: 10 days of consecutive daily injections

Rest period: 4-6 months between cycles

Annual frequency: 2-3 cycles per year

This cycling pattern is based on the bioregulator model developed by Khavinson's research group. The rationale is that bioregulator peptides initiate a cascade of gene expression changes that persist well beyond the period of active administration. The 10-day window provides sufficient signaling to activate telomerase and stimulate pineal function, while the extended rest period allows the endogenous processes to operate independently without continuous exogenous input.

Alternative cycle structures

Extended initial loading: Some practitioners run a 20-day initial cycle (either 20 consecutive days or two 10-day blocks separated by a 10-day break) when initiating Epitalon for the first time, followed by the standard 10-day cycles every 4-6 months thereafter. The rationale is that the initial "priming" of telomerase activation may benefit from a longer signaling window.

Quarterly cycling: 10 days every 3 months (4 cycles per year). This more frequent approach is sometimes used for individuals over 60 or those with documented accelerated telomere shortening. The trade-off is increased peptide use without clear evidence that quarterly dosing is superior to biannual dosing.

Conservative approach: 10 days every 6 months (2 cycles per year). This is the minimum effective frequency based on the Russian bioregulator literature and is appropriate for younger individuals (40-55) using Epitalon preventively rather than correctively.

Expected timeline

Epitalon's effects operate on a longer timescale than most peptide protocols. This is not a peptide where you feel something in week one.

During the 10-day cycle:

Some individuals report improved sleep quality within 3-5 days, likely mediated by enhanced melatonin secretion
Subjective effects are otherwise subtle to absent during the active cycle
No performance enhancement, mood change, or cosmetic effect should be expected during the treatment window

1-3 months post-cycle:

Melatonin levels, if measured, may show improvement in evening peak values
Sleep architecture changes may become more noticeable (deeper sleep, more consolidated sleep cycles, improved dreaming)
No visible or functional anti-aging changes at this timepoint

6-12 months (after 2-3 cycles):

Telomere length measurements, if obtained, may begin to show stabilization or modest lengthening relative to expected age-related decline
Cumulative sleep and circadian improvements
Some practitioners report that patients describe improved skin quality, energy levels, and stress resilience, though these are subjective and difficult to attribute specifically to Epitalon

2+ years of consistent cycling:

The most meaningful longevity data from the Russian research covers multi-year follow-up periods. The Khavinson studies on elderly patients using Epithalamin showed reduced cardiovascular mortality and improved immune markers over 6-12 year observation windows. While these studies have methodological limitations, they provide the longest human outcome data available for any bioregulator peptide.

Combination with MOTS-c

MOTS-c is a mitochondrial-derived peptide that activates AMPK and improves metabolic function, exercise capacity, and cellular energy production. Combining MOTS-c with Epitalon creates a longevity protocol that addresses two distinct aging axes: genomic stability (telomere maintenance) and metabolic decline (mitochondrial function).

Combined protocol:

Epitalon: 5 mg daily for 10 days, every 4-6 months (standard cycle)
MOTS-c: 5-10 mg, 3 times per week, in 8-week cycles

Timing strategy: The two peptides do not need to be administered simultaneously. Run the 10-day Epitalon cycle at any point during or between MOTS-c cycles. There is no known pharmacological interaction between the two peptides — they act through entirely independent pathways (nuclear telomerase activation vs. mitochondrial AMPK signaling).

Additional longevity stack consideration — Pinealon: Pinealon (Glu-Asp-Arg) is another Khavinson bioregulator peptide that specifically targets the pineal gland and central nervous system. Some practitioners stack Pinealon with Epitalon during the 10-day cycle for enhanced pineal support. Pinealon is typically administered at 10-20 mg daily, often as an oral or intranasal formulation. The evidence base for this combination is limited to preclinical studies and clinical observations from the St. Petersburg group.

Monitoring

Longevity protocols require objective biomarker tracking to justify continued use. Subjective well-being alone is insufficient to evaluate whether Epitalon is producing the desired biological effects.

Primary biomarkers

Telomere length: The most directly relevant marker. Measured via blood draw using quantitative PCR (qPCR) or the more precise terminal restriction fragment (TRF) analysis. Measure at baseline (before the first Epitalon cycle) and retest every 12 months. Telomere length changes slowly — testing more frequently than annually introduces measurement noise that exceeds biological signal.

Important context: telomere length is highly variable between assay methods and even between testing sessions with the same method. A single measurement is less informative than a trend over 2-3 years. Use the same laboratory and methodology for all measurements. Interpret results as stabilization relative to expected age-related decline, not as absolute telomere "gain."

Melatonin levels: Salivary or urinary melatonin metabolite (6-sulfatoxymelatonin) measured in the evening or overnight. This provides a functional readout of pineal gland activity. Measure at baseline and 1-2 months after completing an Epitalon cycle.

Secondary biomarkers

Sleep metrics: Wearable device data (total sleep, deep sleep percentage, REM sleep, sleep onset latency, wake-after-sleep-onset). Track continuously and compare 30-day averages before and after Epitalon cycles.

Inflammatory markers: hs-CRP, IL-6. Chronic low-grade inflammation accelerates telomere shortening. These markers provide context for interpreting telomere data and may improve with bioregulator use.

Oxidative stress markers: 8-OHdG (urinary), F2-isoprostanes. Oxidative damage to DNA correlates with telomere attrition. Available through specialty labs.

Comprehensive metabolic panel and CBC: Standard bloodwork before and after cycles to monitor general health and identify any unexpected changes.

Safety considerations

Tolerability: Epitalon is generally well-tolerated. The most commonly reported adverse effects are mild injection site reactions (redness, itching) that resolve within hours. Systemic side effects are rare in published reports and clinical observations.

Theoretical concern — cancer risk: Telomerase activation is a double-edged sword. While it supports healthy cell longevity, telomerase is also upregulated in approximately 85-90% of human cancers, enabling the unlimited replicative potential that characterizes malignant cells. The critical question is whether exogenous telomerase activation via Epitalon could promote or accelerate occult malignancies.

The available data, though limited, is somewhat reassuring. The Khavinson long-term studies did not report increased cancer incidence in Epithalamin-treated groups — in fact, some studies reported reduced tumor incidence. The bioregulator model suggests that Epitalon normalizes telomerase activity (restoring it in senescent cells) rather than constitutively overactivating it. However, this remains a theoretical risk that cannot be dismissed with current evidence.

Practical recommendation: Individuals with active malignancy or a strong family history of cancers strongly associated with telomerase activation should discuss this protocol with their oncologist before initiating Epitalon. Age-appropriate cancer screening should be maintained throughout any longevity protocol.

Drug interactions: No significant pharmacological interactions have been reported. Epitalon does not inhibit cytochrome P450 enzymes or interact with common medications based on available data. However, individuals taking immunosuppressive medications or those with autoimmune conditions should proceed with caution given the peptide's immunomodulatory properties.

Pregnancy and breastfeeding: No safety data exists. Epitalon should not be used during pregnancy or lactation.

Contraindications: Active malignancy (absolute). Uncontrolled autoimmune disease (relative — assess risk-benefit with physician). Children and adolescents (no safety or efficacy data; telomere biology differs in growing individuals).

Reconstitution and storage

Reconstitution: Add bacteriostatic water slowly to the lyophilized peptide vial. Do not shake — gently swirl or roll. Standard reconstitution: 2 mL bacteriostatic water per 10 mg vial.

Storage: Lyophilized (unreconstituted) peptide: stable at room temperature for months; refrigeration extends shelf life to 2+ years. Reconstituted peptide: refrigerate at 2-8 degrees Celsius. Use within 4 weeks of reconstitution. Do not freeze reconstituted peptide.

Protocol summary

Parameter	Specification
Dose	5-10 mg daily
Route	Subcutaneous
Cycle length	10 consecutive days
Cycle frequency	Every 4-6 months (2-3x/year)
Preferred timing	Evening (1-2 hrs before bed)
Primary combination	MOTS-c (metabolic axis)
Key biomarker	Telomere length (annual)
Functional biomarker	Melatonin levels (post-cycle)
Minimum commitment	2 years for meaningful assessment